THOMAS FRANK E — SEC Form 4 filings
SEC reporting owner CIK 1242616. 9 Form 4 filings on record with FilingPulse; latest filed 2026-06-25.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-01-24 to 2026-06-25. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 7,000 shares, $47,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
- Largest priced transaction: purchase of 5,000 shares @ $5.00 ($25,000) in Larimar Therapeutics, Inc., filed 2026-03-02.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | Director | 5 | 2 legs · 7,000 sh · $47,000 | — | 3 |
| Orchard Therapeutics plc (ORTX) | See Remarks | 1 | — | — | 11 |
| Spero Therapeutics, Inc. (SPRO) | Director | 3 | — | — | 4 |
Form 4 filings — THOMAS FRANK E
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-25 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 55,150 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Larimar Therapeutics, Inc. (LRMR) | Purchase (P): 5,000 @ $5 | EDGAR |
| 2025-06-16 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-05-14 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-05-30 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2024-02-15 | 4 | Larimar Therapeutics, Inc. (LRMR) | Purchase (P): 2,000 @ $11 | EDGAR |
| 2024-01-24 | 4 | Orchard Therapeutics plc (ORTX) | Disposition to issuer (D): 92,081 · Disposition to issuer (D): 99,980 (derivative) @ $0 · Disposition to issuer (D): 199,990 (derivative) @ $0 · Disposition to issuer (D): 149,990 (derivative) @ $0 · Disposition to issuer (D): 309,990 (derivative) @ $0 · Disposition to issuer (D): 27,730 (derivative) @ $0 · +5 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1242616 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →